Healthcare provider profile · identity verified

Andrew Phan, MD

Family Practice · PORTLAND, ME · NPI 1619918307

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	408	120
Lisinopril	Lisinopril	269	81
Amlodipine Besylate	Amlodipine Besylate	196	58
Losartan Potassium	Losartan Potassium	130	37
Rosuvastatin Calcium	Rosuvastatin Calcium	130	40
Omeprazole	Omeprazole	122	36
Levothyroxine Sodium	Levothyroxine Sodium	109	28
Metoprolol Succinate	Metoprolol Succinate	92	29
Hydrochlorothiazide	Hydrochlorothiazide	89	29
Metformin Hcl Er	Metformin Hcl	89	24
Gabapentin	Gabapentin	76	23
Sertraline Hcl	Sertraline Hcl	75	19
Albuterol Sulfate Hfa	Albuterol Sulfate	72	28
Tamsulosin Hcl	Tamsulosin Hcl	71	24
Lovastatin	Lovastatin	65	19
Simvastatin	Simvastatin	62	18
Allopurinol	Allopurinol	54	17
Eliquis	Apixaban	50	16
Jardiance	Empagliflozin	50	suppressed
Glipizide Er	Glipizide	47	11
Alendronate Sodium	Alendronate Sodium	45	11
Atenolol	Atenolol	44	13
Clonazepam	Clonazepam	43	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	41	12
Escitalopram Oxalate	Escitalopram Oxalate	38	11
Ozempic	Semaglutide	38	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	37	12
Prednisone	Prednisone	37	26
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	36	suppressed
Trazodone Hcl	Trazodone Hcl	35	suppressed
Metformin Hcl	Metformin Hcl	34	12
Citalopram Hbr	Citalopram Hydrobromide	33	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	33	14
Meloxicam	Meloxicam	32	21
Chlorthalidone	Chlorthalidone	30	11
Fluticasone Propionate	Fluticasone Propionate	29	14
Alprazolam	Alprazolam	27	11
Azithromycin	Azithromycin	27	25
Duloxetine Hcl	Duloxetine Hcl	27	suppressed
Finasteride	Finasteride	26	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	26	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	24	23
Bupropion Hcl Sr	Bupropion Hcl	24	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	24	12
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	23	suppressed
Montelukast Sodium	Montelukast Sodium	23	suppressed
Diazepam	Diazepam	22	suppressed
Furosemide	Furosemide	22	suppressed
Lorazepam	Lorazepam	22	suppressed
Pravastatin Sodium	Pravastatin Sodium	22	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	22	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	19	18
Doxycycline Monohydrate	Doxycycline Monohydrate	18	17
Fluoxetine Hcl	Fluoxetine Hcl	18	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	18	suppressed
Arnuity Ellipta	Fluticasone Furoate	17	suppressed
Famotidine	Famotidine	16	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	16	suppressed
Verapamil Er	Verapamil Hcl	16	suppressed
Mirtazapine	Mirtazapine	15	suppressed
Oxycodone Hcl	Oxycodone Hcl	15	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	15	suppressed
Xarelto	Rivaroxaban	15	suppressed
Bupropion Xl	Bupropion Hcl	14	suppressed
Carvedilol	Carvedilol	14	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	14	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	14	suppressed
Bydureon Bcise	Exenatide Microspheres	13	suppressed
Doxepin Hcl	Doxepin Hcl	13	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	13	suppressed
Enalapril Maleate	Enalapril Maleate	13	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	13	suppressed
Pregabalin	Pregabalin	13	suppressed
Acyclovir	Acyclovir	12	suppressed
Azelastine Hcl	Azelastine Hcl	12	suppressed
Febuxostat	Febuxostat	12	suppressed
Oxycontin	Oxycodone Hcl	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	12	suppressed
Ezetimibe	Ezetimibe	11	suppressed
Fentanyl	Fentanyl	11	suppressed
Tramadol Hcl	Tramadol Hcl	11	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	11	suppressed
Ventolin Hfa	Albuterol Sulfate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error